AstraZeneca Reports Q3 2026 Results with Strong Oncology and Rare Disease Growth
AstraZeneca (AZN) reported third-quarter revenue of $13.5 billion, representing a 7% increase at constant exchange rates. The growth was primarily driven by significant momentum in the oncology and rare disease segments, including strong performance from Tagrisso and Enhertu. Despite these gains, the biopharmaceuticals segment saw a 6% decline as generic competition for Farxiga impacted revenue in the U.S. and China. The company is currently undergoing a 'Reshaping for Sustainable Growth' program, incurring $2 billion in restructuring costs to achieve $1.5 billion in annualized benefits by 2029. Looking ahead, AstraZeneca maintains a robust pipeline with 20 key Phase III readouts planned for 2027 and has reiterated its full-year 2026 guidance of mid-to-high single-digit revenue growth.
Tickers: $AZN
Topics: Biopharmaceuticals Financial Performance Oncology Rare Disease Revenue Growth
Read the full article at Motley Fool
Part of the story Loomis Reports Record Revenue and Operating Margins for Q3 2026 (40 articles)